Abstract
One of the most powerful forms of cancer immunotherapies is chimeric antigen receptor (CAR) T-cell therapy. Despite being fairly recent in terms of its development and approval, CAR T-cells show great potential as a treatment, since they can efficiently recognize and destroy tumor cells. However, due to the various toxicities associated with this treatment option, CAR T-cell therapy is usually advised as a last resort. The most prominent toxicity of CAR T-cell therapy is the onset of immunotoxicity, which includes Cytokine Release Syndrome (CRS). This review will focus on the recent definition of CRS in general, the mechanisms of CRS progression, how tumor cell pyroptosis via. CAR T-cell therapy can trigger CRS, and the strategies to prevent CRS that have shown efficiency in the application of CAR T-cell patients. By the end, this article will highlight the combination of inhibitors of CRS to improve tumor therapy in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
